The Cell Penetrating Peptide Market is Predict to reach $2.7 Billion by 2030, at a CAGR of 10.5%

Cell Penetrating Peptide Market Growth, Trends and Report Highlights

According to a new report, published by KBV research, The Global Cell Penetrating Peptide Market size is expected to reach $2.7 billion by 2030, rising at a market growth of 10.5% CAGR during the forecast period.

The Contract Research Organization (CROs) segment is anticipated to have a CAGR of 11.5% during (2023 - 2030). CROs offer a range of services encompassing different aspects of CPP research and development. These services include peptide design, synthesis, characterization, formulation development, in vitro and in vivo investigations, and preclinical testing. By providing comprehensive services, CROs streamline the drug development process for their clients. These factors will pose lucrative growth prospects for the segment.

The Drug Delivery segment is leading the Global Cell Penetrating Peptide Market, by Application in 2022 thereby, achieving a market value of $1.2 Billion by 2030. The primary advantage of cell-penetrating peptides lies in their ability to enhance cellular uptake. CPPs can traverse cell membranes efficiently, overcoming a significant barrier to delivering therapeutic agents into cells. This property is especially valuable for drugs that have poor cellular penetration on their own. These aspects will lead to increased demand in the segment.

The Protein-derived CPPs segment is experiencing a CAGR of 10.8% during (2023 - 2030). In 2022, the protein derived CPPs segment garnered a significant revenue share in the cell penetrating peptide market. Protein-derived CPPs often leverage naturally occurring proteins or protein sequences. This biological origin allows these peptides to mimic endogenous cellular processes more closely, potentially enhancing their biocompatibility and reducing immunogenicity. Mimicking the behavior of endogenous proteins contributes to the efficiency of cellular uptake and intracellular delivery. Therefore, the segment will expand rapidly in the coming years.

Full Report: https://www.kbvresearch.com/cell-penetrating-peptide-market/

The North America region dominated the Global Cell Penetrating Peptide Market, by region in 2022 thereby, achieving a market value of $1.3 Billion by 2030, growing at a CAGR of 9.6 % during the forecast period. The Europe region is experiencing a CAGR of 11% during (2023 - 2030). Additionally, The Asia Pacific region would witness a CAGR of 11.7% during (2023 - 2030).

List of Key Companies Profiled

• Biosynth Ltd
• Creative Peptides
• Cupid Peptide Company Limited
• Alta Bioscience Ltd
• AnaSpec Inc. (Kaneka Eurogentec S.A.) (Kaneka Corporation)
• Peptomyc SL
• PolyPeptide Group AG
• Bachem Holding AG (Ingro Finanz AG)
• Sarepta Therapeutics, Inc.
• Revance Therapeutics, Inc.

Cell Penetrating Peptide Market Report Segmentation

By End-use

• Pharmaceutical and Biotechnology Companies
• Contract Research Organization (CROs)
• Hospitals & Clinics
• Others

By Application

• Drug Delivery
• Gene Delivery
• Diagnostics
• Molecular Imaging
• Others

By Type

• Synthetic CPPs
• Protein-derived CPPs
• Chimeric CPPs

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Related Reports:

North America Cell Penetrating Peptide Market Size, 2030

• January-2024
• 102 Pages

LAMEA Cell Penetrating Peptide Market Size & Forecast, 2030

• January-2024
• 113 Pages

Europe Cell Penetrating Peptide Market Size, Share by 2030

• January-2024
• 113 Pages

Asia Pacific Cell Penetrating Peptide Market Size to 2030

• January-2024
• 113 Pages